Final results from a phase 2b randomized, placebo-controlled clinical trial of RBX2660: A microbiota-based drug for the prevention of recurrent Clostridioides difficile infection
Infectious Diseases and Therapy
Open Access Publication
Rights and Permissions
Dubberke, E.R., Orenstein, R., Khanna, S. et al. Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection. Infect Dis Ther 12, 703–709 (2023). https://doi.org/10.1007/s40121-022-00744-3 This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Dubberke, Erik R; Orenstein, Robert; Khanna, Sahil; Guthmueller, Beth; and Lee, Christine, "Final results from a phase 2b randomized, placebo-controlled clinical trial of RBX2660: A microbiota-based drug for the prevention of recurrent Clostridioides difficile infection." Infectious Diseases and Therapy. 12, 2. 703 - 709. (2023).
ICTS (Institute of Clinical and Translational Sciences)